## **Changqing Xie**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4919238/publications.pdf

Version: 2024-02-01

1307594 1372567 10 290 7 10 citations g-index h-index papers 10 10 10 426 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	4.2	97
2	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	7.3	77
3	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e349-e360.	2.3	31
4	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	3.7	22
5	Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance. Cancers, 2022, 14, 381.	3.7	17
6	Systemic treatment options for advanced biliary tract carcinoma. Journal of Gastroenterology, 2020, 55, 944-957.	5.1	15
7	Targeting cancer stem cells in cholangiocarcinoma (Review). International Journal of Oncology, 2020, 57, 397-408.	3.3	15
8	Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing. Stem Cells International, 2022, 2022, 1-14.	2.5	7
9	Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation. Journal of the Endocrine Society, 2019, 3, 284-290.	0.2	6
10	Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, , .	1.3	3